Medical Editor: John P. Cunha, DO, FACOEP
Tequin (gatifloxacin) is an antibiotic used to treat bacterial infections of the lungs sinuses skin and urinary tract. Tequin is also used to treat certain sexually transmitted diseases. The brand name Tequin is discontinued but generic versions may be available. Common side effects of Tequin (gatifloxacin) include:
- mild nausea
- stomach pain
- vaginal discharge or itching
- sleep problems (insomnia or nightmares), or
The dose of Tequin depends on the disease being treated. Tequin may interact with antacids containing magnesium or aluminum, vitamin or mineral supplements containing zinc, magnesium or iron; didanosine chewable/buffered tablets or pediatric powder for oral solution, cisapride, erythromycin, warfarin, probenecid, digoxin, nonsteroidal anti-inflammatory drugs (NSAIDs), heart rhythm medicines, antidepressants, or phenothiazines. Tell your doctor all medications and supplements you use. Tequin may be harmful to a fetus. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.
Our Tequin (gatifloxacin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Over 5000 patients have been treated with gatifloxacin in single- and multiple-dose clinical efficacy trials worldwide.
In gatifloxacin studies, the majority of adverse reactions were described as mild in nature. Gatifloxacin was discontinued for adverse events thought related to drug in 2.7% of patients.
Drug-related adverse events classified as possibly, probably, or definitely related with a frequency of ³3% in patients receiving gatifloxacin in single- and multiple-dose clinical trials are as follows: nausea 8%, vaginitis 6%, diarrhea 4%, headache 3%, dizziness 3%.
In patients who were treated with either intravenous gatifloxacin or with intravenous followed by oral therapy, the incidence of adverse events was similar to those who received oral therapy alone. Local injection site reactions (redness at injection site) were noted in 5% of patients.
Additional drug-related adverse events (possibly, probably, or definitely related) considered clinically relevant that occurred in ³0.1% to <3% of patients receiving gatifloxacin in single- and multiple-dose clinical trials are as follows:
Cardiovascular System: hypertension, palpitation
Urogenital System: dysuria
Additional drug-related adverse events considered clinically relevant that occurred in <0.1% (rare adverse events) of patients receiving gatifloxacin in single- and multiple-dose clinical trials are as follows: abnormal thinking, alcohol intolerance, arthritis, asthma (bronchospasm), ataxia, bone pain, bradycardia, breast pain, cheilitis, colitis, convulsion, cyanosis, depersonalization, depression, diabetes mellitus, dysphagia, ear pain, ecchymosis, edema, epistaxis, euphoria, eye pain, eye photosensitivity, gastrointestinal hemorrhage, generalized edema, gingivitis, halitosis, hallucination, hematemesis, hematuria, hostility, hyperesthesia, hypertonia, hyperventilation, hypoglycemia, lymphadenopathy, maculopapular rash, metrorrhagia, migraine, mouth edema, myalgia, myasthenia, neck pain, panic attack, paranoia, parosmia, photophobia, pseudomembranous colitis, psychosis, ptosis, rectal hemorrhage, stress, substernal chest pain, tachycardia, taste loss, tongue edema, vesiculobullous rash.
Clinically relevant changes in laboratory parameters, without regard to drug relationship, occurred in fewer than 1% of TEQUIN (gatifloxacin (removed from us market - may 2006)) -treated patients. These included the following: neutropenia, increased ALT or AST levels, alkaline phosphatase, bilirubin, serum amylase, and electrolytes abnormalities. It is not known whether these abnormalities were caused by the drug or the underlying condition being treated.
Postmarketing Adverse Event Reports
The following events have been reported during postapproval use of TEQUIN (gatifloxacin (removed from us market - may 2006)) . Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abnormal renal function (including acute renal failure), acute allergic reaction including anaphylactic reaction and angioneurotic edema, hepatitis, hypotension, increased International Normalized Ratio (INR)/prothrombin time, pancreatitis, severe hyperglycemia (including hyperosmolar nonketotic hyperglycemia), severe hypoglycemia (including hypoglycemic coma), Stevens-Johnson syndrome, syncope, tendon rupture, thrombocytopenia, and torsades de pointes.
Read the entire FDA prescribing information for Tequin (gatifloxacin)
© Tequin Patient Information is supplied by Cerner Multum, Inc. and Tequin Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.